{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:59:53Z","timestamp":1780693193467,"version":"3.54.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      The aim of this study was to assess the prognostic value of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT-based features performed at the diagnosis of giant cell arteritis (GCA) for the risk of relapse.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT was performed in patients with GCA between 2014 and 2024 before 10 days of corticosteroid therapy. Visual scores were assessed: TVS, PETVAS, \u201cextended\u201d PETVAS with 17 segments (PETVAS51), cephalic score \u201cC-VAS\u201d dedicated to the branches of the external carotid artery, and global score \u201cG-VAS\u201d combining all the previous territories. Maximum standardized uptake values (SUVmax) and target-to-background ratios (TBR) normalized to liver or circulating blood pool were also collected. Relapse was defined by the occurrence of suggestive clinical, biological, or imaging events. Survival analyses (Kaplan\u2013Meier) and Cox models adjusted for age, sex, and camera type (analog or digital) were used to identify prognostic factors for relapse.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Seventy-six patients were included, 41% of them relapsed after a median follow-up of 14 months. None of the conventional scores (TVS, PETVAS, PETVAS 51) or semiquantitative parameters predicted relapse. In contrast, the G-VAS &gt;45 and C-VAS &gt;8 were significantly associated with relapse in univariate analysis [HR = 2.64 (95% CI: 1.00; 6.98),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.043 and 3.48 (1.30; 9.29),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0084, respectively]. Only a C-VAS score &gt;8 was an independent predictor of prompt relapses in multivariate analysis [HR = 3.31 (1.16\u20139.38)].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      In patients with GCA, increased uptake of the cephalic branches of the external carotid artery on initial\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT was an independent prognostic factor for relapse.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006427","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:00:10Z","timestamp":1775577610000},"page":"e431-e438","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Cranial Arteries Involvement on 18F-FDG PET\/CT at Giant Cell Arteritis Diagnosis in a Multicenter Cohort"],"prefix":"10.1097","volume":"51","author":[{"given":"Rachel","family":"Bardy","sequence":"first","affiliation":[{"name":"Nantes Universit\u00e9, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, M\u00e9decine Nucl\u00e9aire, Nantes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Detournay","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine - Molecular Imaging, H\u00f4pitaux Universitaires Paris-Saclay AP-HP, DMU SMART IMAGING, H\u00f4pital Bic\u00eatre, Le Kremlin-Bic\u00eatre"},{"name":"CEA\/Inserm\/CNRS\/Universit\u00e9 Paris-Saclay, BioMaps, Orsay"},{"name":"School of Medicine, Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-6219","authenticated-orcid":false,"given":"Alexis F.","family":"Guedon","sequence":"additional","affiliation":[{"name":"Sorbonne University, National Institute of Health and Medical Research, Pierre Louis Institute of Epidemiology and Public Health, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne","family":"Mekinian","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, AP-HP, H\u00f4pital Saint Antoine, service de m\u00e9decine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Paris, France and French Armenian Research Center, Erevan, Armenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Morard","sequence":"additional","affiliation":[{"name":"Department of Internal and Vascular Medicine, University Hospital of Nantes, Nantes Universit\u00e9, l\u2019institut du thorax Team III Vascular and Pulmonary Diseases, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, M\u00e9decine Nucl\u00e9aire, Nantes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Jamet","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, M\u00e9decine Nucl\u00e9aire, Nantes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9826-3890","authenticated-orcid":false,"given":"Florent L.","family":"Besson","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine - Molecular Imaging, H\u00f4pitaux Universitaires Paris-Saclay AP-HP, DMU SMART IMAGING, H\u00f4pital Bic\u00eatre, Le Kremlin-Bic\u00eatre"},{"name":"CEA\/Inserm\/CNRS\/Universit\u00e9 Paris-Saclay, BioMaps, Orsay"},{"name":"School of Medicine, Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-9990","authenticated-orcid":false,"given":"Olivier","family":"Espitia","sequence":"additional","affiliation":[{"name":"Department of Internal and Vascular Medicine, University Hospital of Nantes, Nantes Universit\u00e9, l\u2019institut du thorax Team III Vascular and Pulmonary Diseases, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"R1-20260605","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N Engl J Med"},{"key":"R2-20260605","first-page":"1","article-title":"EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update","volume":"0","author":"Dejaco","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/ard-2022-223480","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis","volume":"81","author":"Ponte","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"105494","DOI":"10.1016\/j.jbspin.2022.105494","article-title":"Epidemiology and predictors of relapse in giant cell arteritis: a systematic review and meta-analysis","volume":"90","author":"Moreel","year":"2023","journal-title":"Joint Bone Spine"},{"key":"R5-20260605","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A phase 3 trial of upadacitinib for giant-cell arteritis","volume":"392","author":"Blockmans","year":"2025","journal-title":"N Engl J Med"},{"key":"R6-20260605","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2665-9913(23)00101-7","article-title":"Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Venhoff","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"R7-20260605","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/art.21699","article-title":"Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients","volume":"55","author":"Blockmans","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R8-20260605","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/art.40379","article-title":"18 F-fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis","volume":"70","author":"Grayson","year":"2018","journal-title":"Arthritis Rheum"},{"key":"R9-20260605","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejim.2017.08.013","article-title":"Repetitive 18F-FDG-PET\/CT in patients with large-vessel giant-cell arteritis and controlled disease","volume":"46","author":"de Boysson","year":"2017","journal-title":"Eur J Intern Med"},{"key":"R10-20260605","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejim.2024.03.037","article-title":"Prognostic value of 18 FDG-PET at diagnosis and follow-up in giant cell arteritis: an observational restrospective study","volume":"126","author":"Billet","year":"2024","journal-title":"Eur J Intern Med"},{"key":"R11-20260605","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s00259-018-4106-0","article-title":"Simple dichotomous assessment of cranial artery inflammation by conventional 18F-FDG PET\/CT shows high accuracy for the diagnosis of giant cell arteritis: a case-control study","volume":"46","author":"Nielsen","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20260605","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/rheumatology\/keac430","article-title":"PET\/CT of cranial arteries for a sensitive diagnosis of giant cell arteritis","volume":"62","author":"Thibault","year":"2023","journal-title":"Rheumatology"},{"key":"R13-20260605","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/1756-185X.13805","article-title":"Cranial and large vessel activity on positron emission tomography scan at diagnosis and 6 months in giant cell arteritis","volume":"23","author":"Sammel","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"R14-20260605","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s00259-018-3973-8","article-title":"FDG-PET\/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC","volume":"45","author":"Slart","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-20260605","doi-asserted-by":"crossref","first-page":"1432865","DOI":"10.3389\/fmed.2024.1432865","article-title":"Role and potential of 18F-fluorodeoxyglucose-positron emission tomography-computed tomography in large-vessel vasculitis: a comprehensive review","volume":"11","author":"Collada-Carrasco","year":"2024","journal-title":"Front Med"},{"key":"R16-20260605","article-title":"Secukinumab after tocilizumab failure in giant cell arteritis","author":"Espitia","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R17-20260605","doi-asserted-by":"crossref","first-page":"105734","DOI":"10.1016\/j.jbspin.2024.105734","article-title":"Limb arteries involvement assessed by FDG\/PET CT at diagnosis of giant cell arteritis and risk of relapse: an observational study","volume":"91","author":"Peyrac","year":"2024","journal-title":"Joint Bone Spine"},{"key":"R18-20260605","doi-asserted-by":"crossref","first-page":"1000123","DOI":"10.4172\/2471-9544.1000123","article-title":"Fatal spontaneous bilateral vertebral artery dissection in giant cell arteritis (GCA)","volume":"3","author":"Proft","year":"2017","journal-title":"J Vasc"},{"key":"R19-20260605","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheum"},{"key":"R20-20260605","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/S2665-9913(23)00300-4","article-title":"Large vessel giant cell arteritis","volume":"6","author":"van der Geest","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"R21-20260605","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/qjmed\/hcae105","article-title":"Identifying giant cell arteritis patients with higher risk of relapse and vascular events: a cluster analysis","volume":"117","author":"Gu\u00e9don","year":"2024","journal-title":"QJM"},{"key":"R22-20260605","doi-asserted-by":"crossref","first-page":"e3818","DOI":"10.1097\/MD.0000000000003818","article-title":"Giant-cell arteritis without cranial manifestations: working diagnosis of a distinct disease pattern","volume":"95","author":"de Boysson","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R23-20260605","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12149-023-01875-4","article-title":"Difference in arterial FDG accumulation in healthy study participants between digital PET\/CT and standard PET\/CT","volume":"38","author":"Nitta","year":"2024","journal-title":"Ann Nucl Med"},{"key":"R24-20260605","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MNM.0000000000001935","article-title":"Variants of physiological FDG vascular activity on digital PET","volume":"46","author":"Yin","year":"2025","journal-title":"Nucl Med Commun"},{"key":"R25-20260605","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","article-title":"EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice","volume":"77","author":"Dejaco","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R26-20260605","doi-asserted-by":"crossref","first-page":"e003379","DOI":"10.1136\/rmdopen-2023-003379","article-title":"Imaging in diagnosis, monitoring and outcome prediction of large vessel vasculitis: a systematic literature review and meta-analysis informing the 2023 update of the EULAR recommendations","volume":"9","author":"Bosch","year":"2023","journal-title":"RMD Open"},{"key":"R27-20260605","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3899\/jrheum.120511","article-title":"Giant cell arteritis with or without aortitis at diagnosis. A retrospective study of 22 patients with longterm followup","volume":"39","author":"Espitia","year":"2012","journal-title":"J Rheumatol"},{"key":"R28-20260605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1759720X211009029","article-title":"Large-vessel involvement is predictive of multiple relapses in giant cell arteritis","volume":"13","author":"de Mornac","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R29-20260605","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1093\/rheumatology\/keac125","article-title":"The role of PET\/CT in disease activity assessment in patients with large vessel vasculitis","volume":"61","author":"Galli","year":"2022","journal-title":"Rheumatology"},{"key":"R30-20260605","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.semarthrit.2017.08.009","article-title":"18 F-FDG PET\/CT in the follow-up of large-vessel vasculitis: a study of 37 consecutive patients","volume":"47","author":"Mart\u00ednez-Rodr\u00edguez","year":"2018","journal-title":"Semin Arthritis Rheum"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:00:20Z","timestamp":1780689620000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006427","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"2025-12-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}